Doxorubicin effects on leukemia and breast cancer cells in culture on the TK1 protein levels using AroCell TK 210 ELISA: a tool for drug development

Abstract

In this study changes in thymidine kinase 1 (TK1) levels after 24 hours of Doxorubicin (Dox) exposure of CEM and MDA MB-231 cells were determined using the commercially available AroCell TK 210 ELISA test. In cell extracts, TK1 levels increased twofold with 1 µM Dox in both cell lines, while the TK1 levels in the culture media increased with 5 and 10 µM of Dox only in case of CEM cells. In conclusion, this study reveals that the TK 210 ELISA can measure changes in intra- and extracellular TK1 levels apparently related to the mechanism of cytotoxicity of anti-cancer agents.

Keywords:

• Doxorubicin
• TK 210 ELISA
• Thymidine kinase 1

Acknowledgments

The authors want to thank Martin Shaw for valuable suggestions and assistance in preparing the manuscript. AroCell AB was the main sponsor of this work but use of equipment at the Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences is gratefully acknowledged.

Disclosure statement

Staffan Eriksson is an inventor of a TK1 patent licensed to DiaSorin Inc. and is a shareholder in AroCell AB. Kiran Kumar is employed by AroCell AB.